- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00698087
Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B
June 13, 2008 updated by: GlaxoSmithKline
Study to Compare the Safety, Immunogenicity and Reactogenicity of Different Formulations of GSK Biologicals' (Previously SmithKline Beecham Biologicals') MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B
The purpose of the study is to compare the safety, reactogenicity and immunogenicity of different formulations of adjuvanted recombinant hepatitis B vaccine to that of Engerix™-B when administered at 0, 2 months with a booster at month 12 if necessary
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Vienna, Austria
- GSK Clinical Trials Call Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Between 18 and 40 years old.
- Written informed consent will have been obtained from the subjects.
- Good physical condition as established by physical examination and history taking at the time of entry.
- Female participants will avoid becoming pregnant during the study period and they will have been on a contraceptive program for at least 2 months before entry
Exclusion Criteria:
- Pregnancy or lactation.
- Positive titres for anti hepatitis B antibodies
- Any vaccination against hepatitis B in the past.
- Any previous administration of MPL.
- Elevated serum liver enzymes.
- History of significant and persisting hematologic, hepatic, renal, cardiac or respiratory disease.
- Axillary temperature > 37.5°C at the time of injection.
- Any acute disease at the moment of entry.
- Chronic alcohol consumption.
- Any treatment with immunosuppressive or immunostimulant therapy.
- Any chronic drug treatment, which in the investigator's opinion, precludes inclusion into the study.
- History of allergic disease likely to be stimulated by any component of the vaccine.
- Simultaneous administration of any other vaccine(s).
- Administration of any immunoglobulin during the study period.
- Simultaneous participation in any other clinical trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
|
Intramuscular injection, 2 or 3 doses, 2 different formulations
|
Active Comparator: Group B
|
Intramuscular injection, 2 or 3 doses
|
Experimental: Group C
|
Intramuscular injection, 2 or 3 doses, 2 different formulations
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Anti-HBs antibody concentrations
Time Frame: At M3 and M13
|
At M3 and M13
|
Occurrence of local and general solicited symptoms
Time Frame: 4-day follow-up after vaccination
|
4-day follow-up after vaccination
|
Occurrence of unsolicited symptoms
Time Frame: 30-day follow-up after vaccination
|
30-day follow-up after vaccination
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
SAEs
Time Frame: Throughout the study up to 30 days after last vaccination
|
Throughout the study up to 30 days after last vaccination
|
Anti-HBs antibody concentrations
Time Frame: Months 2, 3, 6, 9, 12, 13
|
Months 2, 3, 6, 9, 12, 13
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 1995
Primary Completion (Actual)
February 1, 1996
Study Completion (Actual)
February 1, 1996
Study Registration Dates
First Submitted
June 12, 2008
First Submitted That Met QC Criteria
June 13, 2008
First Posted (Estimate)
June 16, 2008
Study Record Updates
Last Update Posted (Estimate)
June 16, 2008
Last Update Submitted That Met QC Criteria
June 13, 2008
Last Verified
June 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 208129/016
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Ain Shams UniversityCompleted
-
National Taiwan University HospitalChiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu Chi... and other collaboratorsRecruitingChronic Hepatitis b | Hepatitis B ReactivationTaiwan
-
Mahidol UniversityUnknownChronic Hepatitis B, HBsAg, Hepatitis B VaccineThailand
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
IlDong Pharmaceutical Co LtdRecruitingChronic Hepatitis bKorea, Republic of
-
Antios Therapeutics, IncTerminatedChronic Hepatitis bUnited States
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.Unknown
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruitingChronic Hepatitis b | Cirrhosis Due to Hepatitis BChina
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis b
Clinical Trials on MPL-Adjuvanted recombinant hepatitis B vaccine
-
GlaxoSmithKlineCompleted
-
Dynavax Technologies CorporationCompletedChronic Kidney DiseaseUnited States
-
Dynavax Technologies CorporationCompletedEnd Stage Renal DiseaseGermany
-
Dynavax Technologies CorporationCompletedChronic Kidney DiseaseUnited States
-
Dynavax Technologies CorporationCompleted
-
Dynavax Technologies CorporationCompletedHealthyUnited States, Canada
-
University of Maryland, BaltimoreWithdrawn
-
Dynavax Technologies CorporationCompletedHepatitis BGermany, Canada
-
HenogenCompleted
-
Jiangsu Province Centers for Disease Control and...CompletedHepadnaviridae Infections | DNA Virus Infections | Virus DiseaseChina